BRAF and melanoma: Indeed, it was found that NF1 suppression led to a 31-fold increase in resistance to PLX4720, as well as a partial (7-fold) resistance to MEK inhibition, demonstrating that human melanoma samples with innate resistance to BRAF inhibition and sensitivity to a MEK inhibitor harboured NF1 mutations [53].